SCHEMBL10681393

SCHEMBL10681393

Cc1ccc(C2=C3C=CC(=N3)C(c3ccccc3)=C3C=CC(=N3)C(c3ccccc3)=C3C=CC(=N3)C(c3ccccc3)=C3C=CC2=N3)c(C(=O)O)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ FABP3 P05413 1/20 0.42
▸ FABP4 P15090 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.41
▸ DHODH Q02127 7/20 0.40
▸ CSNK2A1 P68400 1/20 0.39
▸ EIF4E P06730 2/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ POLB P06746 1/20 0.36
▸ FOLH1 Q04609 1/20 0.36
▸ LDHA P00338 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ METAP2 P50579 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10679197 0.92 CSNK2A1 (0.45) KDM4EALDH1A1HSD17B10DHODHCSNK2A1
SCHEMBL9391411 0.86 KMT2A (0.48) KDM4EALDH1A1HSD17B10FABP3FABP4
SCHEMBL28725358 0.81 KDM4E (0.34) KDM4EALDH1A1HSD17B10FABP3FABP4
SCHEMBL935295 0.77 FABP3 (0.44) KDM4EALDH1A1HSD17B10FABP3FABP4
SCHEMBL3912294 0.77 NPC1 (0.43) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL3913647 0.77 NPC1 (0.43) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL3733709 0.75 HDAC7 (0.60) KDM4EALDH1A1HSD17B10FABP3FABP4
SCHEMBL1977054 0.74 ALDH1A1 (0.53) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL25395879 0.73 NPC1 (0.47) KDM4EALDH1A1CSNK2A1LDHAHPGD
SCHEMBL25394857 0.73 NPC1 (0.47) KDM4EALDH1A1CSNK2A1LDHAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135310-B2 Gold porphyrin-PEG conjugates and methods of use THE UNIVERSITY OF HONG KONG (HK) 2021-10-05 — — US disclosed
EP-3386986-B1 GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE UNIV HONG KONG (CN) 2021-07-21 — — EP disclosed
US-20170157261-A1 GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE THE UNIVERSITY OF HONG KONG (HK) 2017-06-08 — — US disclosed
US-4783529-A Rapid synthesis of radiolabeled porphyrin complexes for medical application RESEARCH CORPORATION TECHNOLOGIES (US) 1988-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11135310-B2 Gold porphyrin-PEG conjugates and methods of use HCCS, PPOX, LIG3 KDM4E 4181/4885ALDH1A1 1068/4885HSD17B10 1867/4885
US-20170157261-A1 GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE HCCS, PPOX, LIG3 KDM4E 4181/4885ALDH1A1 1068/4885HSD17B10 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback